216 related articles for article (PubMed ID: 2669670)
21. Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up.
Colao A; Loche S; Cappa M; Di Sarno A; Landi ML; Sarnacchiaro F; Facciolli G; Lombardi G
J Clin Endocrinol Metab; 1998 Aug; 83(8):2777-80. PubMed ID: 9709946
[TBL] [Abstract][Full Text] [Related]
22. Long term therapy of patients with macroprolactinoma using repeatable injectable bromocriptine.
Ciccarelli E; Miola C; Grottoli S; Avataneo T; Lancranjan I; Camanni F
J Clin Endocrinol Metab; 1993 Feb; 76(2):484-8. PubMed ID: 8432794
[TBL] [Abstract][Full Text] [Related]
23. The efficacy and tolerability of CV 205-502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine.
van der Lely AJ; Brownell J; Lamberts SW
J Clin Endocrinol Metab; 1991 May; 72(5):1136-41. PubMed ID: 1673685
[TBL] [Abstract][Full Text] [Related]
24. [Bromocriptine for macroprolactinomas. Discussion of 3 cases treated successfully].
Sapunar J; López JM; Huete I; Tagle R
Rev Med Chil; 1992 Feb; 120(2):168-73. PubMed ID: 1340555
[TBL] [Abstract][Full Text] [Related]
25. Normal growth and pubertal development during bromocriptine therapy in two patients with prolactinoma.
Kamel N; Uysal AR; Cesur V; Erdoğan G; Başkal N
Endocr J; 1995 Aug; 42(4):581-6. PubMed ID: 8556068
[TBL] [Abstract][Full Text] [Related]
26. A case of large prolactinoma supposed to be cured by bromocriptine therapy.
Arita K; Uozumi T; Ohta M
Endocrinol Jpn; 1988 Jun; 35(3):503-9. PubMed ID: 3197661
[TBL] [Abstract][Full Text] [Related]
27. Pregnancy with macroprolactinoma.
Abid S; Sadiq I; Anwar S; Hafeez M; Butt F
J Coll Physicians Surg Pak; 2008 Dec; 18(12):787-8. PubMed ID: 19032898
[TBL] [Abstract][Full Text] [Related]
28. [The therapy of a macroprolactinoma with the intramuscular application of a long-acting bromocriptine preparation].
Kreft B; Peters A; Kerner W
Dtsch Med Wochenschr; 1996 Jul; 121(27):865-8. PubMed ID: 8681742
[TBL] [Abstract][Full Text] [Related]
29. [Increased T1 signal of the residual normal anterior pituitary gland following medical treatment of pituitary prolactinoma].
Bonneville F; Cattin F; Barrali E; Lucas X; Narboux Y; Bonneville J
J Radiol; 2001 Apr; 82(4):501-5. PubMed ID: 11353909
[TBL] [Abstract][Full Text] [Related]
30. Prolactin secretion after surgery or bromocriptine treatment of prolactinoma.
De Leo V; Petraglia F; Sardelli S; Danero S; Genazzani AR; D'Antona N
Obstet Gynecol; 1987 Jan; 69(1):99-103. PubMed ID: 3099236
[TBL] [Abstract][Full Text] [Related]
31. [Prolactinoma in a child showing high MIB-1 labeling index: a case report].
Akamine S; Miyamoto T; Sugiura Y; Takehara S; Hiramatsu H; Nishizawa S; Yokota N
No Shinkei Geka; 2000 Jun; 28(6):547-53. PubMed ID: 10875113
[TBL] [Abstract][Full Text] [Related]
32. Bromocriptine as a Potential Glucose-lowering Agent for the Treatment of Prolactinoma with Type 2 Diabetes.
Oshige T; Nakamura Y; Sasaki Y; Kawano S; Ohki T; Tsuruta M; Tokubuchi I; Nakayama H; Yamada K; Ashida K; Tajiri Y; Nomura M
Intern Med; 2019 Nov; 58(21):3125-3128. PubMed ID: 31243214
[TBL] [Abstract][Full Text] [Related]
33. A combined case of macroprolactinoma, growth hormone excess and Graves' disease.
Hussein Z; Tress B; Colman PG
Med J Malaysia; 2005 Jun; 60(2):232-6. PubMed ID: 16114168
[TBL] [Abstract][Full Text] [Related]
34. Successful treatment of a prolactin-producing pituitary macroadenoma with intravaginal bromocriptine mesylate: a novel approach to intolerance of oral therapy.
Katz E; Schran HF; Adashi EY
Obstet Gynecol; 1989 Mar; 73(3 Pt 2):517-20. PubMed ID: 2915884
[TBL] [Abstract][Full Text] [Related]
35. Effective bromocriptine treatment of a pituitary macroadenoma during pregnancy.
Maeda T; Ushiroyama T; Okuda K; Fujimoto A; Ueki M; Sugimoto O
Obstet Gynecol; 1983 Jan; 61(1):117-21. PubMed ID: 6823341
[TBL] [Abstract][Full Text] [Related]
36. Growth of prolactinoma despite lowering of serum prolactin by bromocriptine.
Kupersmith MJ; Kleinberg D; Warren FA; Budzilovitch G; Cooper P
Neurosurgery; 1989 Mar; 24(3):417-23. PubMed ID: 2927618
[TBL] [Abstract][Full Text] [Related]
37. [Discrepancy between IGF-1 and GH during 75 g oral glucose tolerance test measures to acromegaly screening in a patient with macroprolactinoma--case report and literature review].
Gonçalves FT; Feibelmann TC; Fernandes ML; Fonseca AR; Arantes HP; Jorge PT
Arq Bras Endocrinol Metabol; 2007 Apr; 51(3):494-9. PubMed ID: 17546251
[TBL] [Abstract][Full Text] [Related]
38. Combined bromocriptine and growth hormone (GH) treatment in GH-deficient children with macroprolactinoma in situ.
Oberfield SE; Nino M; Riddick L; Pang S; Nagel M; Khandji A; Kairam R; Levine LS
J Clin Endocrinol Metab; 1992 Jul; 75(1):87-90. PubMed ID: 1619034
[TBL] [Abstract][Full Text] [Related]
39. Prolactinomas in infertile women: clinical and endocrine characteristics before and after 24 months of treatment with bromocriptine.
Hajder M; Hajder E; Dervisefendic M; Samardzic R; Alic E
Med Arch; 2013; 67(3):181-4. PubMed ID: 23848038
[TBL] [Abstract][Full Text] [Related]
40. Optic chiasmal herniation--an under recognized complication of dopamine agonist therapy for macroprolactinoma.
Jones SE; James RA; Hall K; Kendall-Taylor P
Clin Endocrinol (Oxf); 2000 Oct; 53(4):529-34. PubMed ID: 11012580
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
